Couzin-Frankel, J. Cancer immunotherapy. Science 342, 1432–1433 (2013).
Google Scholar
Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014).
Google Scholar
Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2015).
Google Scholar
Syn, N. L., Teng, M. W., Mok, T. S. & Soo, R. A. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 18, e731–e741 (2017).
Google Scholar
Duan, Q., Zhang, H., Zheng, J. & Zhang, L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer 6, 605–618 (2020).
Google Scholar
Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013).
Google Scholar
Corrales, L. et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11, 1018–1030 (2015).
Google Scholar
Flood, B. A., Higgs, E. F., Li, S., Luke, J. J. & Gajewski, T. F. STING pathway agonism as a cancer therapeutic. Immunol. Rev. 290, 24–38 (2019).
Google Scholar
Shae, D. et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat. Nanotechnol. 14, 269–278 (2019).
Google Scholar
Schadt, L. et al. Cancer-cell-intrinsic cGAS expression mediates tumor immunogenicity. Cell Rep. 29, 1236–1248 (2019).
Google Scholar
Nicolai, C. J. et al. NK cells mediate clearance of CD8+ T cell-resistant tumors in response to STING agonists. Sci Immunol. https://doi.org/10.1126/sciimmunol.aaz2738 (2020).
Harrington, K. J. et al. Preliminary results of the first-in-human study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with Pembrolizumab (Pembro) in patients with advanced solid tumors or lymphomas. In The European Society for Medical Oncology (ESCO) 2018 Congress Abstract 5475 (2018).
Meric-Bernstam, F. et al. Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas. J. Clin. Oncol. 37, 2507 (2019).
Google Scholar
Ramanjulu, J. M. et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature 564, 439–443 (2018).
Google Scholar
Chin, E. N. et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science 369, 993–999 (2020).
Google Scholar
Pan, B. S. et al. An orally available non-nucleotide STING agonist with antitumor activity. Science https://doi.org/10.1126/science.aba6098 (2020)
Gajewski, T. F. & Higgs, E. F. Immunotherapy with a sting. Science 369, 921–922 (2020).
Google Scholar
Koshy, S. T., Cheung, A. S., Gu, L., Graveline, A. R. & Mooney, D. J. Liposomal delivery enhances immune activation by STING agonists for cancer immunotherapy. Adv. Biosyst. https://doi.org/10.1002/adbi.201600013 (2017).
Tan, Y. S. et al. Mitigating SOX2-potentiated immune escape of head and neck squamous cell carcinoma with a STING-inducing nanosatellite vaccine. Clin. Cancer Res. 24, 4242–4255 (2018).
Google Scholar
Liu, Y. et al. An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases. Nat. Commun. 10, 5108 (2019).
Google Scholar
He, Y. et al. Self-assembled cGAMP-STINGΔTM signaling complex as a bioinspired platform for cGAMP delivery. Sci. Adv. 6, eaba7589 (2020).
Google Scholar
Li, S. et al. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-020-00675-9 (2021).
Chaigne-Delalande, B. & Lenardo, M. J. Divalent cation signaling in immune cells. Trends Immunol. 35, 332–344 (2014).
Google Scholar
Wang, C., Zhang, R., Wei, X., Lv, M. & Jiang, Z. Metalloimmunology: the metal ion-controlled immunity. Adv. Immunol. 145, 187–241 (2020).
Google Scholar
Macian, F. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 5, 472–484 (2005).
Google Scholar
Shi, X. et al. Ca2+ regulates T-cell receptor activation by modulating the charge property of lipids. Nature 493, 111–115 (2013).
Google Scholar
Chandy, K. G. & Norton, R. S. Immunology: channelling potassium to fight cancer. Nature 537, 497–499 (2016).
Google Scholar
Vodnala, S. K. et al. T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science https://doi.org/10.1126/science.aau0135 (2019).
Munoz-Planillo, R. et al. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38, 1142–1153 (2013).
Google Scholar
Rossol, M. et al. Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nat. Commun. 3, 1329 (2012).
Google Scholar
Scambler, T. et al. ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis. Elife https://doi.org/10.7554/eLife.49248 (2019)
Hood, M. I. & Skaar, E. P. Nutritional immunity: transition metals at the pathogen–host interface. Nat. Rev. Microbiol. 10, 525–537 (2012).
Google Scholar
Bessman, N. J. et al. Dendritic cell-derived hepcidin sequesters iron from the microbiota to promote mucosal healing. Science 368, 186–189 (2020).
Google Scholar
Wang, C. et al. Manganese increases the sensitivity of the cGAS-STING pathway for double-stranded DNA and is required for the host defense against DNA viruses. Immunity 48, 675–687 (2018).
Google Scholar
Du, M. & Chen, Z. J. DNA-induced liquid phase condensation of cGAS activates innate immune signaling. Science 361, 704–709 (2018).
Google Scholar
Chaigne-Delalande, B. et al. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science 341, 186–191 (2013).
Google Scholar
Lv, M. et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 30, 966–979 (2020).
Google Scholar
Hou, L. et al. Manganese-based nanoactivator optimizes cancer immunotherapy via enhancing innate immunity. ACS Nano 14, 3927–3940 (2020).
Google Scholar
Chen, C. et al. Cytosolic delivery of thiolated Mn-cGAMP nanovaccine to enhance the antitumor immune responses. Small 17, e2006970 (2021).
Google Scholar
Yang, X. et al. Converting primary tumor towards an in situ STING-activating vaccine via a biomimetic nanoplatform against recurrent and metastatic tumors. Nano Today 38, 101109 (2021).
Google Scholar
Aschner, J. L. & Aschner, M. Nutritional aspects of manganese homeostasis. Mol. Aspects Med. 26, 353–362 (2005).
Google Scholar
Wang, C. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas. Acta Radiol. Suppl. 415, 1–31 (1998).
Google Scholar
Takagi, Y. et al. Evaluation of indexes of in vivo manganese status and the optimal intravenous dose for adult patients undergoing home parenteral nutrition. Am. J. Clin. Nutr. 75, 112–118 (2002).
Google Scholar
Pan, D., Schmieder, A. H., Wickline, S. A. & Lanza, G. M. Manganese-based MRI contrast agents: past, present and future. Tetrahedron 67, 8431–8444 (2011).
Google Scholar
Jin, L. et al. MPYS is required for IFN response factor 3 activation and type I IFN production in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-GMP. J. Immunol. 187, 2595–2601 (2011).
Google Scholar
Li, L. et al. Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat. Chem. Biol. 10, 1043–1048 (2014).
Google Scholar
Thanos, D. & Maniatis, T. Virus induction of human IFNβ gene expression requires the assembly of an enhanceosome. Cell 83, 1091–1100 (1995).
Google Scholar
Wang, J. et al. NF-κB RelA subunit is crucial for early IFN-β expression and resistance to RNA virus replication. J. Immunol. 185, 1720–1729 (2010).
Google Scholar
Ting, J. P., Duncan, J. A. & Lei, Y. How the noninflammasome NLRs function in the innate immune system. Science 327, 286–290 (2010).
Google Scholar
Liu, S. et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science 347, aaa2630 (2015).
Google Scholar
Shin, H. M. et al. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-κB without affecting IκB degradation. FEBS Lett. 571, 50–54 (2004).
Google Scholar
Kuai, R. et al. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Sci. Adv. 4, eaao1736 (2018).
Google Scholar
Sivick, K. E. et al. Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity. Cell Rep. 25, 3074–3085 (2018).
Google Scholar
Luo, X. et al. HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. J. Clin. Invest. 130, 1635–1652 (2020).
Google Scholar
Lewis, R. & Tatken, R. Registry of Toxic Effects of Chemical Substances Vol. 1 (US Department of Health and Human Services, National Institute for Occupational Safety and Health, 1980).
Greger, J. L. Nutrition versus toxicology of manganese in humans: evaluation of potential biomarkers. Neurotoxicology 20, 205–212 (1999).
Google Scholar
Lutz, M. B. et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223, 77–92 (1999).
Google Scholar
Liu, D., Poon, C., Lu, K., He, C. & Lin, W. Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy. Nat. Commun. 5, 4182 (2014).
Google Scholar
Liu, J. et al. Light-controlled drug release from singlet-oxygen sensitive nanoscale coordination polymers enabling cancer combination therapy. Biomaterials 146, 40–48 (2017).
Google Scholar
Yang, Y. et al. One-pot synthesis of pH-responsive charge-switchable PEGylated nanoscale coordination polymers for improved cancer therapy. Biomaterials 156, 121–133 (2018).
Google Scholar
Kuai, R. et al. Subcutaneous nanodisc vaccination with neoantigens for combination cancer immunotherapy. Bioconjug. Chem. 29, 771–775 (2018).
Google Scholar
